Compare Crispr Therapeutics AG (CRSP) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Rockwell Automation — how do they compare? Crispr Therapeutics AG trades at $50.5 (market cap $4.97B), while Rockwell Automation trades at $462.34 (market cap $52.27B). The key difference: Rockwell Automation is far larger — about 10.5× Crispr Therapeutics AG's market cap, and Rockwell Automation pays a 1.18% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | ROK | |
|---|---|---|
Market Cap | $4.97B | $52.27B |
Sector | Health | Industrials |
52-Week High | $76.78 | $495.08 |
52-Week Low | $44.34 | $328.67 |
Enterprise Value | $3.32B | $55.90B |
Dividend Yield | — | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Rockwell Automation (ROK) trades at $460.45, down 2.47% today, with a neutral technical signal and bullish moving averages. The company shows strong profitability with 48.92% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights leadership in industrial automation and AI integration, including new FactoryTalk software launches and WEF recognition for its Singapore facility.
ROK presents a mixed outlook with solid fundamentals but premium valuation (P/E 47.81). Analyst consensus is cautious with 64% hold ratings, though price targets suggest modest upside to $471.71. Key risks include execution challenges in scaling MES integration and industrial sector volatility. The stock offers growth exposure to industrial automation trends with dividend income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
